The estimated Net Worth of Ramesh Kumar is at least $5.54 Tausend dollars as of 6 October 2022. Ramesh Kumar owns over 4,500 units of Ocugen Inc stock worth over $5,535 and over the last 12 years he sold OCGN stock worth over $0. In addition, he makes $0 as Independent Director at Ocugen Inc.
Sign up
Ramesh Kumar OCGN stock SEC Form 4 insiders trading
Ramesh has made over 12 trades of the Ocugen Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 4,500 units of OCGN stock worth $2,295 on 6 October 2022.
The largest trade he's ever made was exercising 60,000 units of Ocugen Inc stock on 30 January 2014 worth over $342,600. On average, Ramesh trades about 5,821 units every 118 days since 2013. As of 6 October 2022 he still owns at least 4,500 units of Ocugen Inc stock.
You can see the complete history of Ramesh Kumar stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ramesh Kumar biography
Dr. Ramesh Kumar Ph.D. serves as Independent Director of the Company. Dr. Kumar has served as a director of OpCo, our wholly owned subsidiary, since June 2019. He co-founded Onconova Therapeutics, Inc. in 1998 and served as its Chief Executive Officer and a member of its board from 1998 to February 2019 and as its President from 1998 to June 2018. Dr. Kumar transitioned to an Advisory role with Onconova in January 2019. He has held positions in R&D and management at Princeton University, Bristol-Myers Squibb, DNX (later Nextran, a subsidiary of Baxter) and Kimeragen (later Valigen), where he served as President of the Genomics and Transgenics Division. Dr. Kumar obtained an undergraduate and Master’s degree in Microbiology from Panjab University and received his Ph.D. in Molecular Biology from the University of Illinois, Chicago and trained at the National Cancer Institute. Our Board believes Dr. Kumar’s extensive senior executive and public company experience, and familiarity with the pharmaceutical industry qualify him to serve on our Board.
How old is Ramesh Kumar?
Ramesh Kumar is 64, he's been the Independent Director of Ocugen Inc since 2019. There are 2 older and 14 younger executives at Ocugen Inc. The oldest executive at Ocugen Inc is Prabhavathi Fernandes, 71, who is the Independent Director.
What's Ramesh Kumar's mailing address?
Ramesh's mailing address filed with the SEC is C/O OCUGEN, INC., 11 GREAT VALLEY PARKWAY, MALVERN, PA, 19355.
Insiders trading at Ocugen Inc
Over the last 5 years, insiders at Ocugen Inc have traded over $18,069,176 worth of Ocugen Inc stock and bought 1,511,356 units worth $684,830 . The most active insiders traders include Shankar Musunuri, Junge Zhang und Uday Kompella. On average, Ocugen Inc executives and independent directors trade stock every 21 days with the average trade being worth of $96,347. The most recent stock trade was executed by Junge Zhang on 14 June 2023, trading 200,278 units of OCGN stock currently worth $100,139.
What does Ocugen Inc do?
ocugen, inc., is a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular disorders. the company’s lead programs in ocular graft versus host disease (ocu300) and chronic dry eye disease (ocu310) are expected to enter pivotal clinical trials in 2018. ocu300 received the first and only orphan drug designation for ocular graft versus host disease, providing certain regulatory and economic benefits. ocugen is also developing novel biologic therapies for retinitis pigmentosa (ocu100) and wet amd (ocu200), as well as a groundbreaking modifier gene therapy platform with potential to address a broad spectrum of inherited retinal disorders (ocu400). for more information, please visit www.ocugen.com.
What does Ocugen Inc's logo look like?
Complete history of Ramesh Kumar stock trades at Onconova Therapeutics Inc und Ocugen Inc
Ocugen Inc executives and stock owners
Ocugen Inc executives and other stock owners filed with the SEC include:
-
Dr. Shankar Musunuri M.B.A., MBA, Ph.D.,
Co-Founder, Chairman & CEO -
Shankar Musunuri,
Chairman of the Board, Chief Executive Officer -
Sanjay S. Subramanian M.B.A.,
Chief Accounting Officer, CFO, Treasurer, Head of Corp. Devel. & Corp. Sec. -
Rasappa Arumugham,
Chief Scientific Officer -
Dr. Uday B. Kompella Ph.D.,
Co-founder & Independent Director -
Junge Zhang,
Independent Director -
Suha Taspolatoglu,
Independent Director -
Manish Potti,
Independent Director -
Ramesh Kumar,
Independent Director -
Uday Kompella,
Independent Director -
Prabhavathi Fernandes,
Independent Director -
Kirsten Castillo,
Independent Director -
Kelly Beck,
Vice President, Investor Relations and Administration and Corporate Secretary -
Vijay Tammara,
Senior Vice President - Regulatory and Quality -
Sanjay Subramanian,
Chief Financial Officer, Chief Accounting Officer, Treasurer -
Michael Shine,
Sr. VP of Commercial -
J. P. Gabriel,
Sr. VP of Manufacturing & Supply Chain -
Dr. Bruce D. Forrest B.S., M.B.A., M.D.,
Acting Chief Medical Officer & Vaccine Scientific Advisory Board Member -
Dr. Arun Upadhyay Ph.D.,
Head of Research, Devel. & Discovery -
Dr. Vijay Tammara,
Sr. VP of Regulatory & Quality -
Zara Gaudioso,
Head of HR -
Ken Inchausti,
Head of Investor Relations & Communications -
Jessica Crespo,
CAO/SVP, Finance -
Daniel Jorgensen,
Chief Medical Officer -
Frank Leo,
Director -
Marna C Whittington,
Director -
Huma Qamar,
Chief Medical Officer -
Arun Upadhyay,
See Remarks